19 studies found for:    TH-302
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
2 Recruiting A Phase 1 TH-302 Mass Balance Trial
Condition: Solid Tumor
Interventions: Drug: [14C] TH-302 (Label 1);   Drug: [14C] TH-302 (Label 2);   Drug: Unlabeled TH-302
3 Active, not recruiting Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
4 Recruiting A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: TH-302
5 Recruiting Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
Condition: HIGH GRADE GLIOMA
Interventions: Drug: TH-302;   Drug: Placebo
6 Active, not recruiting A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin;   Drug: Doxorubicin
7 Recruiting Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: TH-302 combination with pemetrexed;   Drug: Matched placebo in combination with pemetrexed
8 Recruiting A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Conditions: Solid Tumor;   Pancreatic Cancer
Interventions: Drug: TH-302 monotherapy;   Drug: TH-302;   Drug: Gemcitabine
9 Completed Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: TH-302
10 Active, not recruiting Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine);   Drug: TH-302
11 Active, not recruiting Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Conditions: Non-Small Cell Lung Cancer;   Prostate Cancer;   Pancreatic Cancer
Intervention: Drug: TH-302
12 Not yet recruiting TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Phase I Dose level -1;   Drug: Phase I dose level 1;   Drug: Phase I Dose level 2;   Drug: Phase I Dose level 3
13 Recruiting A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: TH-302
14 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
15 Recruiting Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Condition: Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions: Drug: TH-302;   Drug: Gemcitabine;   Drug: Placebo (5 percent dextrose - D5W)
16 Recruiting Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate;   Genetic: protein analysis;   Other: laboratory biomarker analysis
17 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Conditions: Tumors;   Hypoxia
Intervention: Drug: TH-302
18 Active, not recruiting Dose Escalation Study of Pazopanib Plus TH-302
Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
19 Recruiting Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: TH-302;   Drug: Nab-paclitaxel;   Drug: Gemcitabine

Indicates status has not been verified in more than two years